A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants

Summary

This is a randomized, double-blind, placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of SKB575. This study consists of two parts. Phase Ia is a single ascending dose study in healthy subjects and Phase Ib is a proof-of-concept study in patients with moderate to severe atopic dermatitis.

Timeline

Start

2026-03-31

Primary completion

2027-12-31

Completion

2028-06-30

Drugs

Indications